Compare GeneDx Holdings Corp (WGS) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GeneDx Holdings Corp vs Workiva Inc — how do they compare? GeneDx Holdings Corp trades at $67.52 (market cap $2.02B), while Workiva Inc trades at $73.89 (market cap $4.01B). The key difference: Workiva Inc is the larger of the two by market cap, and Workiva Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GeneDx Holdings Corp for 19 Days and Workiva Inc for 21 Days on average.
| WGS | WK | |
|---|---|---|
Market Cap | $2.02B | $4.01B |
Volume | 734,640 | 1,301,708 |
Sector | Health | Technology |
52-Week High | $167.51 | $93.31 |
52-Week Low | $34.51 | $44.31 |
Typical Hold Time | 19 Days | 21 Days |
Enterprise Value | $2.05B | $3.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
WK trades at $73.79, up 3.16% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $0.798. Revenue grew to $966 million in 2026, turning a net loss in 2025 into a $47 million profit. Analyst sentiment is overwhelmingly positive, with 16 buy ratings and a consensus price target of $86.
The outlook for WK is favorable, driven by consistent earnings outperformance and revenue growth, though high valuation multiples like a P/E of 87.73 pose risks. Key opportunities include AI-driven product innovations and inclusion in investment analyses, while risks involve competitive pressures and reliance on continued execution. The stock's proximity to its 52-week high suggests momentum but warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
